PatientsVille.com Logo

HAEMOPTYSIS and Tikosyn

PatientsVille

HAEMOPTYSIS Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for HAEMOPTYSIS

HAEMOPTYSIS treatment research studies

Tikosyn clinical trials, surveys and public health registries


Find Drug Side Effect reports



Tikosyn Side Effects

Atrial Fibrillation (267)
Dizziness (156)
Fatigue (116)
Dyspnoea (110)
Headache (94)
Electrocardiogram Qt Prolonged (86)
Heart Rate Increased (83)
Condition Aggravated (79)
Arrhythmia (74)
Asthenia (68)
Nausea (62)
Chest Pain (61)
Diarrhoea (52)
Palpitations (48)
Feeling Abnormal (48)
Torsade De Pointes (45)
Urinary Tract Infection (40)
Blood Pressure Increased (39)
Cardiac Disorder (35)
Insomnia (34)
Heart Rate Irregular (32)
Pneumonia (31)
Hypertension (31)
Death (30)
Blood Potassium Decreased (30)
Malaise (30)
Ventricular Tachycardia (30)
Pain In Extremity (28)
Weight Decreased (27)
Vision Blurred (26)
Arthralgia (25)
Heart Rate Decreased (25)
Cough (25)
Weight Increased (24)
Anxiety (23)
Nasopharyngitis (22)
Tremor (21)
Hyperhidrosis (21)
Blood Creatinine Increased (20)
Chest Discomfort (20)
Renal Impairment (20)
Fall (20)
Muscle Spasms (19)
Vomiting (19)
Infection (19)
Blood Pressure Decreased (19)
Bronchitis (18)
Cardiac Failure Congestive (18)
Depression (18)
Dysphagia (18)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

HAEMOPTYSIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study
Conditions: Lung Cancer;   Tuberculosis;   Bronchiectasis;   Pneumonia;   Acute Bronchitis;   Chronic Obstructive Pulmonary Disease;   Cryptogenic Haemoptysis
Interventions: Other: Chest X-ray;   Other: computed tomography of the chest;   Procedure: Bronchoscopy
Outcome Measures: Percentage of patients presenting with Haemoptysis affected by lung cancer, tuberculosis, bronchiectasis, pneumonia, acute bronchitis, cryptogenic Haemoptysis or other causes.;   Sensitivity and specificity of chest X-ray, chest CT scan and bronchoscopy alone and in combination in the diagnosis of different causes of Haemoptysis.;   Percentage and severity of recurrence of Haemoptysis in the follow-up period.;   Sensitivity and specificity of bronchoscopy in localizing the bleeding side and lobe in relation to the timing of the Haemoptysis.;   Patient survival in the follow-up period.
2 Recruiting Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance
Conditions: Hemoptysis;   Acute Disease
Interventions: Other: Medicals measures;   Other: bronchial artery embolization
Outcome Measures: Bleeding recurrence rate, after initial therapeutic strategy.;   Evaluation of the rate of serious adverse events
3 Unknown  The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis
Condition: Hemoptisis
Intervention: Drug: tranexamic acid
Outcome Measure: bleeding stops
4 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
Outcome Measures: Primary objective is to estaimate the overall response rate (ORR) of six cycles of liposomal doxorubicin combined with bevacizumab in patients with advanced KS.;   Secondary objectives include evaluation of the safety of the regimen, as well as estimation of the complete response rate after 6 cycles, the median number of cycles need to obtain a partial response, and 12-month progression-free survival.
5 Recruiting Effects of Pepper Gas Exposure in Non-combatant Bystanders.
Conditions: Cough;   Irritation in Throat;   Irritation in Skin;   Lacrimation
Intervention:
Outcome Measures: Development of cough, irritation in throat, nasal irritation, nasal discharge, wheezing, breathlessness, hemoptysis, chest pain upon exposure or worsening of already existing cough, breathlessness, wheezing of a previous respiratory illness.;   Duration of symptoms developed
6 Recruiting ELTGOL and Bronchiectasis. Respiratory Therapy
Conditions: Respiratory; Complications, Therapy;   Bronchiectasis
Interventions: Procedure: Low Expiration Open glottis inferolateral (ELTGOL);   Procedure: Stretching
Outcome Measures: To evaluate the efficacy of ELTGOL in stable state patients with bronchiectasis compared to placebo;   Side effects, knowledge
7 Recruiting Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy
Condition: Peripheral Pulmonary Nodules
Intervention: Device: Navigation guided bronchoscopy
Outcome Measures: Evaluating the diagnostic yield of using navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB) in the evaluation of PPN.;   Adverse event rates of hemoptysis and pneumothorax
8 Recruiting Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Abraxane (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
Outcome Measures: Progression free survival (PFS);   Adverse Events;   Overall Survival;   Overall response rate
9 Recruiting A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy
Condition: Non-small Cell Lung Cancer
Interventions: Radiation: EBR plus HDRIB;   Radiation: EBR
Outcome Measures: For each subject, a lung cancer-related symptomatic improvement at 6 weeks post randomization, defined as a 10-point improvement on a 100 point scale from the summary question of lung cancer symptoms;   Improvement in each lung cancer symptom as measured by the Lung Cancer Symptom Scale (LCSS) as defined by a 10-point improvement for cough, shortness of breath, hemoptysis and pain on the LCSS at 6 weeks post randomization;   Improvement in each lung cancer symptom and overall symptoms at any time after randomization;   A Quality of Life (QOL) improvement as measured be overall score of the LCSS, at each scheduled assessment point following randomization (Weeks 3, 6, 12, 26, 34, 42 and 50);   Symptomatic progression-free survival (SPFS), defined as the time from randomization until death, use of chemotherapy, or the first post-randomization score on LCSS #7 which is 10 points or greater than the baseline score, or scored at 100.;   Overall survival, calculated from the date of randomization to the date of death
10 Recruiting Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype
Condition: Lung Cancer
Intervention: Other: Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes
Outcome Measure: Descriptive study of our patients with lung adenocarcinoma. Identify novel molecular characteristics so that potential drug development can be reached.
11 Recruiting Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Condition: Advanced Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF;   Drug: Placebo;   Other: Best Supportive Care
Outcome Measures: Progression-Free Survival (PFS);   Overall survival (OS);   Tumor response;   Safety and Toxicity according to NCI-CTCAE criteria(version 4.03);   Quality of life (QoL) according to Lung Cancer Symptom Scale
12 Recruiting The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults
Condition: Bronchiectasis
Intervention:
Outcome Measures: The prevalence of respiratory virus infection in adults with bronchiectasis during a pulmonary exacerbation and when clinically stable.;   The effect of respiratory virus infection on systemic and pulmonary inflammatory markers.;   The effect of respiratory virus on lung function;   The effect of respiratory virus infection on the bacterial load in bronchiectasis.;   Time to recovery of respective symptom;   The effect of respiratory virus on quality of life in patients with bronchiectasis;   To investigate if upper respiratory tract symptoms are associated with viral infections.
13 Unknown  Stachybotrys Induced Hemorrhage in the Developing Lung
Condition: Idiopathic Pulmonary Hemorrhage
Intervention:
Outcome Measure:
14 Recruiting Prediction of Major Bleeding in ELBW-infants (<1000g) by Sequential Coagulation Monitoring
Conditions: Intraventricular Haemorrhage;   Pulmonary Haemorrhage
Intervention: Device: Coaguchek
Outcome Measures: major bleeding;   mortality